Jupiter Neurosciences Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.
Current Price
$0.24
+16.93%Profile
Valuation (TTM)
Market Cap$7.06M
P/E-0.77
EV—
P/B—
Shares Out29.44M
P/Sales174.48
Revenue$40448.00
EV/EBITDA—
Jupiter Neurosciences Inc (JUNS) Stock Analysis
Market Cap$7.06M
Current Price$0.24
P/E Ratio-0.77
Forward P/E—
PEG Ratio-0.04
EPS$-0.25
Book Value$-0.06
P/B Ratio—
JUNS Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Debt: 2M
Revenue
—
FY19
1M
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
JUNS 52-Week Range
$0.20
$2.97
50-Day MA: $0.37200-Day MA: $0.96
Did you know?
Currently near its 52-week low — in the bottom 1% of its range.
Jupiter Neurosciences Inc (JUNS) Financial Summary
Jupiter Neurosciences Inc (JUNS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $0.24 with a market capitalization of $7.06M.
Key valuation metrics include a P/E ratio of -0.77, and EPS of $-0.25. The company reports a profit margin of -22690.8%.
JUNS Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $7.06M |
| P/E Ratio | -0.77 |
| EPS | $-0.25 |
| P/S Ratio | 174.48 |
| Profit Margin | -22690.8% |
JUNS Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $0.00 | $-3.05M |
| FY20 | $1.13M | $-1.65M |
| FY21 | $638037.00 | $-4.20M |
| FY22 | $233281.00 | $-4.96M |
| FY23 | $0.00 | $-4.78M |
| FY24 | $0.00 | $-2.44M |
| FY25 | $21796.00 | $-8.64M |
JUNS Quality Indicators
Jupiter Neurosciences Inc maintains a profit margin of -22690.8% and an operating margin of -40873.2%. The current ratio is 0.65.
About Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.
JUNS Free Cash Flow
Jupiter Neurosciences Inc generated $-5.41M in trailing twelve-month free cash flow, representing an FCF yield of -76.71%. This low FCF yield may reflect heavy reinvestment or growth spending.
JUNS Shares Outstanding
Jupiter Neurosciences Inc has 0.03 billion shares outstanding at a share price of $0.24, giving it a market capitalization of $7.06M.